Loading...
XSHG603139
Market cap200mUSD
Dec 24, Last price  
14.84CNY
1D
-7.28%
1Q
23.94%
IPO
-36.53%
Name

Shaanxi Kanghui Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:603139 chart
P/E
—
P/S
2.20
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
0.25%
Rev. gr., 5y
12.37%
Revenues
673m
+36.92%
276,820,956328,064,455375,731,468379,785,070381,845,771367,057,156375,618,264431,421,291414,071,702442,756,905491,511,206672,960,241
Net income
-26m
40,398,48855,822,17662,741,93862,205,19365,234,11263,019,58655,629,18142,763,04234,113,73036,481,4660-26,158,640
CFO
0k
-100.00%
16,119,75639,351,30022,724,63728,502,79671,718,35743,597,45862,635,269107,525,83993,722,9697,418,78850,434,2000
Dividend
Jun 29, 20220.074 CNY/sh
Earnings
May 20, 2025

Profile

Shaanxi Kanghui Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. It offers gynecological, orthopedic, dermatology, diabetes, respiratory system, urinary system, cardiovascular and cerebrovascular, gastrointestinal, hepatobiliary, and other drugs in the form of tablets, capsules, granules, mixtures, teas, plasters, ointments, liniments, lotions, and tinctures. The company is based in Xianyang, China.
URL
http://www.sxkh.com/
IPO date
Apr 21, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
672,960
36.92%
491,511
11.01%
442,757
6.93%
Cost of revenue
646,749
451,689
390,808
Unusual Expense (Income)
NOPBT
26,212
39,823
51,949
NOPBT Margin
3.89%
8.10%
11.73%
Operating Taxes
(7,168)
5,593
Tax Rate
10.77%
NOPAT
33,380
39,823
46,356
Net income
(26,159)
 
36,481
6.94%
Dividends
(7,391)
(6,992)
Dividend yield
0.42%
0.32%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
200,559
145,352
91,530
Long-term debt
285,705
387,223
396,662
Deferred revenue
35,247
36,013
18,464
Other long-term liabilities
755
879
3,653
Net debt
228,036
186,191
108,302
Cash flow
Cash from operating activities
50,434
7,419
CAPEX
(72,381)
Cash from investing activities
(45,965)
Cash from financing activities
54,646
7,591
378,307
FCF
79,247
(97,859)
(281,266)
Balance
Cash
166,774
230,774
323,427
Long term investments
91,454
115,609
56,462
Excess cash
224,580
321,808
357,751
Stockholders' equity
609,433
615,457
704,539
Invested Capital
1,315,779
1,264,853
1,258,260
ROIC
2.59%
3.16%
4.37%
ROCE
1.70%
2.49%
3.19%
EV
Common stock shares outstanding
100,610
99,880
99,880
Price
18.77
5.75%
17.75
-18.47%
21.77
29.74%
Market cap
1,888,453
6.52%
1,772,870
-18.47%
2,174,388
29.74%
EV
2,187,176
2,011,279
2,351,037
EBITDA
63,924
65,166
68,320
EV/EBITDA
34.22
30.86
34.41
Interest
23,461
13,218
6,324
Interest/NOPBT
89.51%
33.19%
12.17%